4th International 33rd National Turkish Biophysics Congress, Adıyaman, Turkey, 31 August - 03 September 2022, pp.165
Aim: The aim of this study is investigation of the effects of pterostilbene (PTS) (trans-3,5- dimethoxy-4-hydroxystilbene) applied at different doses in the treatment of streptozotocin- induced diabetic myopathy.
Material and Methods: In our study, 5 groups were formed with 10 rats per group. The groups are Control (C), Diabetes (DM), Diabetes+10mg/kg PTS (PTS10), Diabetes+20mg/kg PTS (PTS20), Diabetes+40mg/kg PTS (PTS40). Body weights, serum malondialdehyde (MDA), nerve conduction velocity and blood glucose levels were determined in all groups by biophysical and biochemical analyzes performed at the end of the 5-week experiment period.
Results: The weight losses were measured as 23.8% in the DM, 17.3% in the PTS10, 7.6% in the PTS20 and 1.3% in the PTS40 group. When compared to the DM group, the decrease in blood glucose level was 46.1% in the PTS10, 55.8% in the PTS20 and 63.4% in the PTS40 group. The serum insulin value reduction rate was calculated as 62% in DM, 42% in PTS10, 23.4% in PTS20 and 1.6% in PTS40 according to control group. The serum MDA increasing rate was found as 492% in DM, 229% in PTS10, 144% in PTS20 and 97% in PTS40 according to control group. Nerve Conduction Rate decreased by 52% in the DM group compared with the control group. The decrease rates in nerve conduction of PTS groups are respectively; PTS10 37%, PTS20 32% and PTS40 26% were found.
Conclusion: We believe that the therapeutic properties of pterostilbene administration are better in the treatment of diabetic diseases than other nutraceutical supplements for the time being and that deeper research should be done.
Keywords: Streptozotocin, Nerve Conduction Velocity, Pterostilbene, Blood glucose